Brought to you by 
Crucell, GSK join forces to put malaria vaccine in humans
08 Apr 2010
Executive Summary
Following years of research, Crucell NV (produces large-molecule therapeutics for infectious diseases) and GlaxoSmithKline Biologicals SA have agreed to advance their combination malaria vaccine into human testing--specifically a US Phase I/IIa trial. The companies are looking for third-party funding for the trial, and for future studies they will solicit public or nonprofit support.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Drug Delivery
- Macromolecule
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Crucell, GSK join forces to put malaria vaccine in humans
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice